Literature DB >> 26147888

Expression Quantitative Trait Loci for CARD8 Contributes to Risk of Two Infection-Related Cancers--Hepatocellular Carcinoma and Cervical Cancer.

Jian Yin1, Juan Wen1, Dong Hang1, Jing Han1, Jie Jiang1, Ci Song1, Yao Liu2, Jibin Liu3, Li Liu4, Liguo Zhu5, Jianguo Chen6, Xiangjun Zhai5, Shuanghua Xie7, Zhibin Hu1, Hongbing Shen1, Min Dai7, Ni Li7.   

Abstract

Caspase recruitment domain family, member 8 (CARD8) can coordinate innate and adaptive immune responses and sensitize cells to apoptosis, which may participate in tumorigenesis of virus-induced hepatocellular carcinoma (HCC) and cervical cancer. By bioinformatics analyses, we identified several single nucleotide polymorphisms (SNPs) within a new identified long non-coding RNA (lncRNA) as expression quantitative trait loci (eQTLs) for CARD8. In this study, we therefore hypothesized that CARD8 eQTLs SNPs within lncRNA may influence the risk of HCC and cervical cancer. We performed two independent case-control studies of 1,300 cases with HBV-positive HCC and 1,344 normal controls, together with 1,486 cervical cancer patients and 1,536 control subjects to test the association between eQTLs SNP (rs7248320) for CARD8 and the risk of HCC and cervical cancer. The variant genotype of rs7248320 was significantly associated with increased risk of HCC and cervical cancer [GG vs. AA/GA: adjusted odds ratio (OR) = 1.28, 95% confidence interval (CI) = 1.03-1.61, P = 0.028 for HCC; adjusted OR = 1.34, 95% CI = 1.09-1.66, P = 0.006 for cervical cancer]. Moreover, the effect of rs7248320 on cervical cancer risk was more prominent in premenopausal women. Further interactive analysis detected a significantly multiplicative interaction between rs7248320 and menopausal status on cervical cancer risk (P = 0.018). These findings suggest that CARD8 eQTLs SNP may serve as a susceptibility marker for virus-related HCC and cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26147888      PMCID: PMC4492972          DOI: 10.1371/journal.pone.0132352

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Hepatocellular carcinoma (HCC) and cervical cancer are two most common cancers throughout the world. In 2008, it was estimated that more than 80% of the HCC and cervical cancer cases occurred in developing countries, including China [1,2]. Persistent Hepatitis B virus (HBV) and human papillomavirus (HPV) infection have been well established as risk factors for liver [3] and cervical cancer [4]. However, only a small fraction of viral persistent carriers eventually develop cancer, suggesting other factors may influence clinical outcomes after virus infections. It was reported that host genetic variations play a critical role in carcinogenesis of HCC and cervical cancer [5,6]. Caspase recruitment domain family, member 8 (CARD8) represents a new member of caspase-associated recruitment domains (CARD) family, which are protein-protein interaction modules found extensively in proteins that play important roles in apoptosis and nuclear factor kappa-B (NFκB) activation [7]. Defects in apoptosis are seen in virtually all types of human cancers [8]. CARD8 can suppress activity of NFκB activated by inflammatory mediators [9]. Moreover, activation of NFκB, a hallmark of inflammatory response, is frequently detected in tumors and may constitute a missing link between inflammation and cancer [10,11], and it is critical in the development of virus-induced cancers including HCC and cervical cancer [11-13]. For example, the activation of NFκB signal transduction requires the interaction between hepatitis B virus X protein and oncogene AIB1 [14], and human papillomavirus 16 E5 oncoprotein mediates cervical carcinogenesis via up-regulation of COX-2 expression through NFκB [11]. Long non-coding RNAs (lncRNAs) are defined as non protein-coding transcripts larger than 200 nucleotides. They control gene expression in the nucleus by modulating transcription or via post-transcriptional mechanisms targeting the splicing, stability, or translation of mRNAs [15]. LncRNA AC008392.1 is one of newly identified lncRNAs, which locates in the upstream region of CARD8 in the nineteenth chromosome and is expressed in multiple cell lines such as GM12878 (Human B lymphocyte) and HeLaS3 (Human cervical cancer cells). By bioinformatics analyses, we identified two single nucleotide polymorphisms (SNPs) (rs7248320 and rs12459322) in AC008392.1 may represent the expression quantitative trait loci (eQTLs) for CARD8 (http://www.regulomedb.org) [16]. It is possible that the SNPs influence the interaction between AC008392.1 and CARD8, thereby altering the expression of CARD8. Here, we hypothesized that CARD8 eQTLs SNPs may contribute to modify the risk of two virus-related HCC and cervical cancer. To test our hypothesis, we conducted two independent case-control studies including 1,300 cases with HBV-positive HCC and 1,344 control subjects, as well as 1,486 cervical cancer cases and 1,536 control subjects to assess the associations between eQTLs SNPs for CARD8 and the susceptibility of the two cancers.

Materials and Methods

Study Subjects

This study was approved by the ethics committee of Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Nanjing Medical University. All the participants provide their written informed consent to participate in this study and the ethics committees approved this consent procedure. The subjects’ enrollment was described previously [17-20]. Briefly, HCC patients were consecutively recruited between January 2006 and December 2010 at the Nantong Tumor Hospital, Qidong Liver Cancer Institute, and the First Affiliated Hospital of Nanjing Medical University of Jiangsu Province, China. The diagnosis of HCC was substantiated by a pathological examination and/or alpha-fetoprotein elevation (> 400 ng/mL) combined with magnetic resonance imaging and/or computerized tomography. Because HCV infection is rare in Chinese populations, The HCC patients with HCV infection were excluded. As a result, 1,300 HBV-positive HCC patients consented to participate in the study. From September 2009 to March 2010, 149,172 inhabitants, who were residing in fifty-two villages in Jiangsu province, China for at least a full year, were enrolled in a community-based cross sectional study. Among them, a total of 11,474 participants were HBsAg seropositive. Afterwards, from September to November 2010, 8,006 individuals (69.8%, 8006/11474) who agreed to be regularly followed up every 1–2 years were called back and checked Hepatitis virus seromarkers once again. Finally, 7,250 individuals who were HBsAg seropositive with twice samples collection in at least 6-month interval, negative for HCV and having information of antiviral therapy were enrolled the community-based cohort. Among them, a total of 1,344 subjects were randomly selected as the controls served as a comparison group of HCC cases. All of the controls were HBV persistent carriers who were positive for both HBV surface antigen (HBsAg) and antibody against hepatitis B core antigen (anti-HBc), but negative for HCV antibody (anti-HCV). No history of HBV vaccination was reported for these subjects. These selected controls were matched to the HCC cases on age (± 5 years) and gender, and declared no previous malignancy. For the cervical cancer study, the 1,486 histologically-confirmed cervical cancer patients were consecutively recruited between March 2006 to December 2010 from the Nantong Tumor Hospital and the First Affiliated Hospital of Nanjing Medical University, Jiangsu, China. The 1,536 controls were also randomly selected from a control pool more than 40,000 individuals who took part in another community-based screening program for non-infectious diseases conducted in Jiangsu Province with follow-up rate of 98.1%. The controls were frequency-matched to the cases on age (± 5 years). All of the controls had no self-reported cancer history. After written informed consent was obtained, each participant was scheduled for an interview by using a structured questionnaire to collect information on demographic data, menstrual and reproductive history, and environmental exposure history. Individuals who smoked one cigarette per day for more than 1 year were defined as smokers, and those who consumed one or more alcohol drinks per week for more than 6 months were categorized as alcohol drinkers. All patients and controls were unrelated ethnic Han Chinese. After interview, a venous blood sample of approximately 5 ml was collected from each participant (HCC patient, cervical cancer patient and control).

Serological Testing

HBsAg, anti-HBc and anti-HCV were detected from each participant’s serum by the enzyme-linked immunosorbent assay (Kehua Bio-engineering Co., Ltd., Shanghai, China) following the manufacturer’s instructions as described previously [17].

SNPs Selection and Genotyping

Based on the data from UCSC database (GRCh37/hg19), Regulome database and the criteria of minor allele frequency (MAF) > 0.05 in Han Chinese, we found two common eQTLs SNPs for CARD8 in nearby lncRNA AC008392.1. The two CARD8 eQTLs SNPs (rs12459322 and rs7248320) are in high linkage disequilibrium (LD) (D’ = 1.000). Thus, we chose rs7248320 as the tagging SNP. Genomic DNA was extracted from a leukocyte pellet by traditional proteinase K digestion and followed by phenol-chloroform extraction and ethanol precipitation. SNP rs7248320 was genotyped using the Sequenom MassARRAY iPLEX platform (Sequenom Inc). The information on primers is shown in Table 1. The genotyping was performed blindly without knowing the status of case or control. Two blank (water) controls in each 384-well plate were used for quality control and more than 10% samples were randomly selected to be repeated, yielding a 100% concordance rate.
Table 1

Information of primers for Sequenom MassARRAY Iplex.

SNPPrimerSequence (5’-3’)
rs7248320 1st-PCR PrimerACGTTGGATGACAGCCTGGAGGAATCTAAG
2nd-PCR PrimerACGTTGGATGTTCTCTTAACGTCCTCTTTC
Extend PrimerTCTTCTCCAAGATCGAAT

Statistical Analysis

Differences of demographic characteristics and genotype frequencies of SNP rs7248320 between the cases and controls were calculated by the Student’s t-test (for continuous variables) and χ2 test (for categorical variables). Associations between the genotypes and cancer risks were estimated by computing odds ratios (OR) and their 95% confidence intervals (CIs) from logistic regression analyses. Heterogeneity of associations between subgroups was assessed by the χ2-based Q test. All of the statistical analyses were performed with R software (version 2.13.0; The R Foundation for Statistical Computing). All tests were two-sided and the criterion of statistical significance was set at P < 0.05.

Results

The demographic characteristics of the 1,300 HBV-positive HCC patients and 1,344 control subjects, and 1,486 cervical cancer patients and 1,536 control subjects were described previously (Tables 2 and 3) [17-20]. There were no significant differences in the proportion of age, gender and smoking between the HCC cases and controls. However, the proportion of drinking was significantly higher in HCC cases than in controls (P < 0.001). Compared with the control subjects, the cervical cancer patients had significantly higher proportion of smoking (P < 0.001), premenopausal status (P = 0.002), and higher parity (P = 0.001).
Table 2

Demographic and selected variables in HCC cases and controls.

VariablesHCCControls P-value
(n = 1300) N (%)(n = 1344) N (%)
Age, year (mean±SD) 52.9±10.552.7±11.10.765
Age, year 0.613
≤53 693(53.3)703(52.3)
>53 607(46.7)641(47.7)
Gender 0.914
Male 1104(84.9)1139(84.7)
Female 196(15.1)205(15.3)
Smoking status 0.287
Ever 774(59.5)772(57.4)
Never 526(40.5)572(42.6)
Drinking status <0.001
Ever 764(58.8)602(44.8)
Never 536(41.2)742(55.2)

Abbreviation: SD, standard deviation.

Table 3

Demographic and selected variables between cervical cancer cases and controls.

VariablesCasesControls P-value
(n = 1486) N(%)(n = 1536) N(%)
Age, year (mean±SD) 53.85±12.7053.21±11.910.159
Smoking status <0.001
Smoker 62(4.2)22(1.4)
Non-smoker 1404(95.8)1514(98.6)
Menopausal status 0.002
Premenopausal 608(41.5)598(38.9)
Natural menopause 769(52.5)878(57.2)
Unnatural menopause 81(5.5)60(3.9)
Family history of any cancer 0.335
Yes 278(19.0)313(20.4)
No 1187(81.0)1223(79.6)
Parity 0.001
0~1 620(42.3)731(48.3)
2 406(27.7)405(26.8)
>2 440(30.0)377(24.9)

Abbreviation: SD, standard deviation.

Abbreviation: SD, standard deviation. Abbreviation: SD, standard deviation. The genotype distributions of rs7248320 in the patients and controls were shown in Table 4. The genotype frequencies of rs7248320 were in Hardy-Weinberg equilibrium in the controls (P = 0.718 for HCC controls and P = 0.343 for cervical cancer controls). In the multivariate logistic regression models, rs7248320 variant genotype GG was associated with an increased risk in HCC by 1.28-fold (95% CI = 1.03–1.61, P = 0.028) compared with the genotypes AA/GA. Similarly, the GG genotype increased the risk of cervical cancer by 1.34-fold (95% CI = 1.09–1.66, P = 0.006) when compared with the genotypes AA/GA (Table 4).
Table 4

Logistic regression analyses on associations between single nucleotide polymorphism rs7248320 (A>G) genotypes and risk of hepatocellular carcinoma and cervical cancer.

GenotypeHepatocellular carcinomaCervical cancer
Patients (N = 1300) n (%)Controls (N = 1344) n (%)OR(95%CI) P OR(95%CI) a P a Patients (N = 1486) n (%)Controls (N = 1536) n (%)OR(95%CI) P OR(95%CI) b P b
rs7248320
AA 524(41.3%)564(42.4%)11535(39.5%)614(42.3%)11
GA 540(42.5%)600(45.1%)0.97(0.82–1.14)0.7080.97(0.82–1.15)0.755587(43.4%)640(44.1%)1.03(0.88–1.20)0.7061.05(0.89–1.24)0.519
GG 206(16.2%)167(12.5%)1.33(1.05–1.68) 0.019 1.27(1.00–1.61)0.053231(17.1%)196(13.5%)1.37(1.10–1.70) 0.005 1.38(1.10–1.73) 0.005
GG vs. AA/GA 1.35(1.08–1.68) 0.008 1.28(1.03–1.61) 0.028 1.35(1.10–1.65) 0.004 1.34(1.09–1.66) 0.006

CI, confidence interval; OR, odds ratio. The boldface values represent these P values were less than 0.05.

aAdjusted for age, gender, smoking status and drinking status.

bAdjusted for age, smoking status, menopausal status, family history of any cancer and parity.

CI, confidence interval; OR, odds ratio. The boldface values represent these P values were less than 0.05. aAdjusted for age, gender, smoking status and drinking status. bAdjusted for age, smoking status, menopausal status, family history of any cancer and parity. The association between rs7248320 and the risk of HCC was further examined in stratified analysis (Table 5). In recessive model, the risk effect for rs7248320 was slightly more prominent in younger subjects (≤ 53 years), male subjects, and those who had ever smoked. However, heterogeneity test was not significant for these strata. Table 6 displayed the association of rs7248320 with the risk of cervical cancer. Although the risk effect for rs7248320 was slightly more pronounced among younger women (≤ 53 years), subjects who had never smoked, subjects who had no family history of any cancer, and less parity (0~1), no heterogeneity between these strata was observed. Interestingly, a stronger risk effect of rs7248320 was observed among premenopausal women (adjusted OR = 1.82, 95% CI = 1.33–2.48) (P = 0.014 for heterogeneity test). By further interactive analysis, a significantly multiplicative interaction was observed between rs7248320 and menopausal status for the risk of cervical cancer (P = 0.018). The crossover analysis suggested that compared with menopause women with genotypes AA/GA, premenopausal women with genotype GG had the highest risk for cervical cancer (adjusted OR = 3.18, 95% CI = 2.24–4.52, P < 0.001) (Table 7).
Table 5

Stratified analyses on association between rs7248320 genotypes and HCC risk.

VariablesPatients/Controls N (%)OR(95%CI) a P b
AA/GAGG
Age 0.280
≤53 560(82.7)/607(87.6)117(17.3)/86(12.4)1.41(1.04–1.92)
>53 504(85.0)/557(87.3)89(15.0)/81(12.7)1.10(0.79–1.53)
Gender 0.133
Male 900(83.0)/985(87.3)184(17.0)/143(12.7)1.36(1.07–1.73)
Female 164(88.2)/179(88.2)22(11.8)/24(11.8)0.77(0.38–1.55)
Smoking status 0.625
Ever 617(81.4)/657(86.2)141(18.6)/105(13.8)1.35(1.01–1.80)
Never 447(87.3)/507(89.1)65(12.7)/62(10.9)1.20(0.83–1.75)
Drinking status 0.922
Ever 607(81.4)/505(84.9)139(18.6)/90(15.1)1.29(0.96–1.73)
Never 457(87.2)/659(89.5)67(12.8)/77(10.5)1.32(0.92–1.88)

aAdjusted for age, gender, smoking status and drinking status (excluded the stratified factor in each stratum).

b P-value for the heterogeneity test.

Table 6

Stratified analyses on association between rs7248320 genotypes and cervical cancer risk.

VariablesPatients/ Controls N (%)OR(95%CI) a P b
AA/GAGG
Age 0.118
≤53 554(79.5)/679(85.3)143(20.5)/117(14.7)1.59(1.21–2.10)
>53 567(86.6)/575(87.9)88(13.4)/79(12.1)1.13(0.81–1.56)
Smoking status 0.498
Ever 45(86.5)/20(90.9)7(13.5)/2(9.1)2.49(0.42–14.79)
Never 1076(82.8)/1234(86.4)224(17.2)/194(13.6)1.34(1.09–1.66)
Menopausal status 0.014
Premenopausal 470(78.9)/508(86.5)126(21.1)/79(13.5)1.82(1.33–2.48)
Menopause 651(86.1)/746(86.4)105(13.9)/117(13.6)1.07(0.80–1.42)
Family history of any cancer 0.830
Yes 210(82.7)/256(86.2)44(17.3)/41(13.8)1.41(0.87–2.28)
No 911(83.0)/998(86.6)187(17.0)/155(13.4)1.33(1.06–1.68)
Parity 0.305
0–1 455(80.2)/612(86.3)112(19.8)/97(13.7)1.6(1.19–2.16)
2 319(83.5)/336(85.1)63(16.5)/59(14.9)1.09(0.73–1.62)
>2 347(86.1)/306(88.4)56(13.9)/40(11.6)1.29(0.83–2.00)

aAdjusted for age, smoking status, menopausal status, family history of any cancer and parity (excluded the stratified factor in each stratum).

b P-value for the heterogeneity test.

Table 7

Crossover analysis in genotypes-menopausal status interaction study on cervical cancer.

GenotypeMenopausal statusPatients (N = 1486) n (%)Controls (N = 1536) n (%)OR(95%CI) a P a
AA/GA Menopause642(48.15)759(51.53)1
AA/GA Premenopausal471(34.79)517(35.10)1.80(1.42–2.29)<0.001
GG Menopause105(7.75)117(7.94)1.06(0.79–1.41)0.700
GG Premenopausal126(9.31)80(5.43)3.18(2.24–4.52)<0.001
Interaction P b = 0.018

aAdjusted for age, smoking status, family history of any cancer and parity.

b P value for multiplicative interaction.

aAdjusted for age, gender, smoking status and drinking status (excluded the stratified factor in each stratum). b P-value for the heterogeneity test. aAdjusted for age, smoking status, menopausal status, family history of any cancer and parity (excluded the stratified factor in each stratum). b P-value for the heterogeneity test. aAdjusted for age, smoking status, family history of any cancer and parity. b P value for multiplicative interaction.

Discussion

In these two independent case-control studies, we investigated the association between rs7248320 and the susceptibility of HCC and cervical cancer from a Chinese population. We found that eQTLs SNP rs7248320 for CARD8 was associated with the increased risk of HCC and cervical cancer. Moreover, a significantly multiplicative interaction between rs7248320 and menopausal status for the risk of cervical cancer was also observed. Since the ENCODE Project and RNA-seq analysis have identified thousands of new lncRNAs, the genetic variants and biological function of lncRNAs are becoming hot spot in studies of complex diseases. Several studies reported that multiple lncRNAs were dysregulated in HCC and cervical cancer, such as HOTAIR and MEG3 [21-25]. Besides, we previously reported that ZNRD1 eQTLs SNPs increased the risk of HCC [20]. LncRNA AC008392.1 locates in the upstream region of CARD8, which may influence the expression of CARD8. A previous study showed that the variant genotype of rs7248320 and rs12459322 were associated with the down-expression of CARD8 in monocytes [26]. There is evidence to suggest that CARD8 is a negative regulator of NFκB activation, which results in the suppression of immune and inflammatory [27,28]. In addition, the reduction of CARD8 suggests a decrease in anti-apoptotic defense [29]. The activation of NFκB signaling contributes to carcinogenesis and promotes disease prognosis and metastasis in HCC and cervical cancer [30-34]. Thus, the variant genotype GG of rs7248320 in lncRNA AC008392.1 may be associated with activation of NFκB and apoptosis inhibition through down-regulation of CARD8, and consequently promote the development and progression of infection-related cancer, including HCC and cervical cancer, which was consistent with the risk effect of the variant genotype GG of rs7248320 in the results of our study. There are several limitations of the study which need to be solved in the further research. Firstly, we conducted the case-control study for only one stage without validation. Further large-scale studies are required for validating the associations between rs7248320 in AC008392.1 and the risk of HCC and cervical cancer. Secondly, the biological function of the two eQTLs SNPs at AC008392.1 was not further investigated in this study. The associations between the SNPs and the risk of HCC and cervical cancer should be interpreted with caution. While, in our previous study [20], We found ZNRD1 (Zinc ribbon domain containing 1) eQTLs SNP rs3757328 in ZNRD1-AS1 (ZNRD1 antisense RNA 1) was associated with increased risk for HCC, and further eQTLs analysis results indicated the significantly association between the genotypes of rs3757328 and the expression of ZNRD1 and ZNRD1-AS1. In vitro experiments also showed that ZNRD1 knockdown inhibited the expression of HBV mRNA and promoted proliferation of HepG2.2.15 cells. Given that the findings from our previous study [20], we hypothesized that lncRNA AC008392.1 might regulate the expression of related protein (CARD8) by itself variation and thereby influence the occurrence and development of hepatic tumor and cervical tumor. Thirdly, HPV infection, the primary and necessary cause of cervical cancer, was not detected in the cervical specimens. And the interaction between HPV type and rs7248320 could not be assessed in cervical carcinogenesis. To our knowledge, this is the first study investigating the association of CARD8 eQTLs SNPs in the lncRNA AC008392.1 with the risk of HCC and cervical cancer. With a relatively large population, this study revealed that the variant genotype GG of rs7248320 in lncRNA AC008392.1 influenced the risk of two virus-related cancersHCC and cervical cancer. The variant genotype GG combined with premenopausal status strengthened the risk effect. These results suggested that AC008392.1 rs7248320 might serve as a susceptibility marker for HCC and cervical cancer. Further studies incorporating diverse populations and functional assays are warranted to validate and extend our findings.
  34 in total

Review 1.  Chapter 2: The burden of HPV-related cancers.

Authors:  D Maxwell Parkin; Freddie Bray
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

Review 2.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

3.  Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.

Authors:  Ruipeng Song; Huiwen Song; Yingjian Liang; Dalong Yin; Heng Zhang; Tongsen Zheng; Jiabei Wang; Zhaoyang Lu; Xuan Song; Tiemin Pei; Youyou Qin; Yuejin Li; Changming Xie; Boshi Sun; Huawen Shi; Shuai Li; Xianzhi Meng; Guangchao Yang; Shangha Pan; Jiyuan Zhu; Shuyi Qi; Hongchi Jiang; Zhiyong Zhang; Lianxin Liu
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

4.  Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression.

Authors:  Bharathi Ramdass; Tessy T Maliekal; S Lakshmi; Michael Rehman; P Rema; Pradip Nair; Geetashree Mukherjee; B K M Reddy; Sudhir Krishna; M Radhakrishna Pillai
Journal:  Gynecol Oncol       Date:  2006-11-13       Impact factor: 5.482

5.  Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer.

Authors:  Nikolaus Möckelmann; Witigo von Schönfels; Stephan Buch; Oliver von Kampen; Bence Sipos; Jan Hendrik Egberts; Philip Rosenstiel; Andre Franke; Mario Brosch; Sebastian Hinz; Christian Röder; Holger Kalthoff; Ulrich R Fölsch; Michael Krawczak; Stefan Schreiber; Clemens Dieter Bröring; Jürgen Tepel; Clemens Schafmayer; Jochen Hampe
Journal:  BMC Gastroenterol       Date:  2009-10-20       Impact factor: 3.067

6.  Genetics and beyond--the transcriptome of human monocytes and disease susceptibility.

Authors:  Tanja Zeller; Philipp Wild; Silke Szymczak; Maxime Rotival; Arne Schillert; Raphaele Castagne; Seraya Maouche; Marine Germain; Karl Lackner; Heidi Rossmann; Medea Eleftheriadis; Christoph R Sinning; Renate B Schnabel; Edith Lubos; Detlev Mennerich; Werner Rust; Claire Perret; Carole Proust; Viviane Nicaud; Joseph Loscalzo; Norbert Hübner; David Tregouet; Thomas Münzel; Andreas Ziegler; Laurence Tiret; Stefan Blankenberg; François Cambien
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

7.  Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer.

Authors:  Long Huang; Ling-Min Liao; An-Wen Liu; Jian-Bing Wu; Xiao-Ling Cheng; Jia-Xin Lin; Min Zheng
Journal:  Arch Gynecol Obstet       Date:  2014-04-20       Impact factor: 2.344

Review 8.  Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Authors:  Ahmed M Elsharkawy; Derek A Mann
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein.

Authors:  Su-Hyeong Kim; Jung-Min Oh; Jae-Hong No; Yung-Jue Bang; Yong-Sung Juhnn; Yong-Sang Song
Journal:  Carcinogenesis       Date:  2009-03-25       Impact factor: 4.944

10.  Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases?

Authors:  Deepti Verma; Maria Lerm; Robert Blomgran Julinder; Per Eriksson; Peter Söderkvist; Eva Särndahl
Journal:  Arthritis Rheum       Date:  2008-03
View more
  11 in total

1.  Expression quantitative trait loci in long non-coding RNA PAX8-AS1 are associated with decreased risk of cervical cancer.

Authors:  Jing Han; Wen Zhou; Meiqun Jia; Juan Wen; Jie Jiang; Jufang Shi; Kai Zhang; Hongxia Ma; Jibin Liu; Jiansong Ren; Min Dai; Zhibin Hu; Dong Hang; Ni Li; Hongbing Shen
Journal:  Mol Genet Genomics       Date:  2016-05-25       Impact factor: 3.291

2.  Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease on chromosome 7p15.3.

Authors:  Megha N Murthy; Cornelis Blauwendraat; Sebastian Guelfi; John Hardy; Patrick A Lewis; Daniah Trabzuni
Journal:  Neurogenetics       Date:  2017-04-08       Impact factor: 2.660

Review 3.  Single nucleotide polymorphisms in ZNRD1-AS1 increase cancer risk in an Asian population.

Authors:  Ping-Yu Wang; Jing-Hua Li; Yue-Mei Liu; Qing Lv; Ning Xie; Han-Han Zhang; Shu-Yang Xie
Journal:  Oncotarget       Date:  2017-02-07

4.  Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq.

Authors:  Jiye Li; Chuzhong Li; Jianpeng Wang; Guidong Song; Zheng Zhao; Haoyuan Wang; Wen Wang; Hailong Li; Zhenye Li; Yazhou Miao; Guilin Li; Yazhuo Zhang
Journal:  Oncotarget       Date:  2017-01-17

5.  Expression quantitative trait loci for PAX8 contributes to the prognosis of hepatocellular carcinoma.

Authors:  Shijie Ma; Jianshui Yang; Ci Song; Zijun Ge; Jing Zhou; Guoxin Zhang; Zhibin Hu
Journal:  PLoS One       Date:  2017-03-24       Impact factor: 3.240

6.  Polymorphism in lncRNA AC008392.1 and its interaction with smoking on the risk of lung cancer in a Chinese population.

Authors:  Xiaoting Lv; Zhigang Cui; Hang Li; Juan Li; Zitai Yang; Yanhong Bi; Min Gao; Baosen Zhou; Zhihua Yin
Journal:  Cancer Manag Res       Date:  2018-05-30       Impact factor: 3.989

7.  The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma.

Authors:  Xueyun Zhao; Mingqiang Hua; Shuxin Yan; Jie Yu; Fengjiao Han; Chaoqin Zhong; Ruiqing Wang; Chen Zhang; Ming Hou; Daoxin Ma
Journal:  J Immunol Res       Date:  2018-08-23       Impact factor: 4.818

8.  Single-Nucleotide Polymorphism LncRNA AC008392.1/rs7248320 in CARD8 is Associated with Kawasaki Disease Susceptibility in the Han Chinese Population.

Authors:  Kai Guo; Lijuan Qiu; Yufen Xu; Xiaoqiong Gu; Linyuan Zhang; Kun Lin; Xiaohuan Wang; Shanshan Song; Yu Liu; Zijian Niu; Shuxuan Ma
Journal:  J Inflamm Res       Date:  2021-09-21

Review 9.  Long noncoding RNAs in hepatitis B virus replication and oncogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

10.  Association between BHMT gene rs3733890 polymorphism and cancer risk: evidence from a meta-analysis.

Authors:  Yue Xu; Cunye Yan; Zongyao Hao; Jun Zhou; Song Fan; Sheng Tai; Cheng Yang; Li Zhang; Chaozhao Liang
Journal:  Onco Targets Ther       Date:  2016-08-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.